sinc
emerg
middl
east
respiratori
syndrom
coronaviru
merscov
mani
question
remain
mode
transmiss
sourc
viru
outbreak
situat
especi
emerg
organ
caus
sever
human
diseas
import
understand
full
spectrum
diseas
shed
kinet
relat
infect
abil
transmit
microorgan
laboratori
respons
capac
earli
stage
outbreak
focus
develop
virolog
immunolog
method
patient
diagnosi
contact
trace
epidemiolog
studi
sourc
mode
transmiss
identif
risk
group
anim
reservoir
howev
optim
use
core
public
health
laboratori
capac
requir
fundament
understand
kinet
viral
shed
antibodi
respons
assay
valid
interpret
test
outcom
review
avail
data
merscov
case
report
compar
data
kinet
shed
immun
respons
publish
literatur
human
coronavirus
hcov
identifi
discuss
import
data
gap
bias
limit
laboratori
prepared
novel
diseas
public
health
manag
benefit
standardis
report
method
use
detail
test
outcom
sampl
type
sampl
date
relat
symptom
risk
factor
along
current
report
demograph
clinic
epidemiolog
find
septemb
first
confirm
case
new
sever
respiratori
syndrom
caus
novel
coronaviru
report
patient
previous
healthi
male
year
old
live
saudi
arabia
die
acut
respiratori
ill
renal
failur
retrospect
analysi
store
sampl
reveal
novel
coronaviru
also
caus
sever
respiratori
diseas
cluster
involv
patient
health
care
profession
jordan
earlier
year
isol
new
viru
saudi
patient
specimen
subsequ
sequenc
detail
phylogenet
analysi
viru
genom
reveal
close
relationship
bat
betacoronavirus
previous
found
asia
europ
africa
whether
emerg
hcov
jump
bat
directli
human
anim
intermedi
host
still
unknown
although
latter
scenario
consid
like
presenc
merscov
neutralis
antibodi
detect
dromedari
camel
spain
oman
egypt
indic
past
infect
merscov
highli
relat
viru
camelid
evolutionari
histori
coronavirus
show
evid
recent
interspeci
jump
one
first
describ
human
coronavirus
share
common
recent
ancestr
histori
bovin
coronavirus
suggest
virus
may
emerg
anim
well
sever
acut
respiratori
syndrom
sar
emerg
first
known
major
outbreak
caus
coronaviru
emerg
merscov
high
fatal
rate
trigger
new
concern
potenti
widespread
possibl
global
outbreak
challeng
public
health
develop
strategi
control
emerg
diseas
includ
earli
detect
case
laboratori
diagnosi
crucial
import
outbreak
situat
especi
novel
organ
caus
sever
human
diseas
import
understand
full
spectrum
diseas
well
relat
infect
abil
transmit
microorgan
eg
viru
outcom
laboratori
test
laboratori
respons
earli
stage
outbreak
therefor
focus
develop
virologicalmicrobiolog
immunolog
method
patient
diagnosi
contact
trace
epidemiolog
studi
sourc
mode
transmiss
identif
risk
group
screen
potenti
anim
reservoir
etc
howev
optim
use
core
laboratori
capac
requir
embed
data
need
laboratori
scientist
within
outbreak
investig
order
obtain
inform
need
assay
valid
correct
interpret
test
outcom
follow
discoveri
merscov
molecular
detect
method
antibodi
detect
assay
develop
sever
group
deploy
intern
intern
collabor
laboratori
respons
howev
spite
cuttingedg
technolog
capac
eg
deep
sequenc
microarray
technolog
lack
essenti
inform
eg
time
sampl
profil
viraemia
shed
link
divers
clinic
manifest
sever
hamper
use
techniqu
current
outbreak
review
current
knowledg
merscov
human
coronavirus
data
requir
optim
laboratori
respons
merscov
earli
phase
emerg
viral
diseas
outbreak
typic
initi
comparison
clinic
manifest
virus
taxonom
group
use
develop
sampl
strategi
crucial
first
question
choic
sampl
subsequ
interpret
laboratori
diagnost
kinet
viral
shed
person
differ
diseas
state
asymptomat
mild
moder
sever
concentr
viru
viral
load
variou
bodi
compart
fluid
secreta
progress
diseas
infect
kinet
load
influenc
host
factor
eg
immunosuppress
comorbid
limit
detect
diagnost
method
use
differ
specimen
nasopharyng
aspir
npa
common
respiratori
specimen
describ
literatur
molecular
diagnosi
nonsar
sar
coronavirus
comparison
data
studi
difficult
specimen
sampl
standardis
descript
vari
nasopharyng
swab
nasopharyng
secret
throat
swab
nasal
swab
oronas
swab
reflect
upper
respiratori
tract
sampl
literatur
review
show
hcov
viral
load
peak
differ
time
point
progress
diseas
nonsar
cov
eg
peak
viral
load
detect
around
day
onset
diseas
appar
clearanc
infect
cours
week
healthi
children
sarscov
viral
load
gradual
increas
day
patient
onset
symptom
progress
decreas
day
patient
fig
comparison
illustr
even
virus
belong
famili
use
sensit
test
like
rtpcr
interpret
test
outcom
may
differ
neg
reversetranscriptas
rt
pcr
patient
specimen
collect
earli
ill
onset
may
use
evid
rule
infect
assay
appli
earli
specimen
patient
contact
recent
ill
onset
sarscov
infect
would
like
falseneg
viral
load
expect
low
phase
ill
top
schemat
represent
compar
profil
sar
shed
peak
viral
load
antibodi
kinet
base
data
describ
top
left
figur
peak
viral
load
inform
given
base
bottom
schemat
represent
relationship
sensit
molecular
detect
serolog
relat
time
sampl
kinet
infect
merscov
data
respiratori
shed
report
anecdot
sofar
merscov
case
reportedli
develop
respiratori
diseas
rang
mild
sever
pneumonia
often
accompani
acut
respiratori
distress
syndrom
ard
andor
renal
failur
andor
pericard
andor
dissemin
intravascular
coagul
dic
clinic
manifest
sever
mer
seem
similar
sar
coronaviru
infect
howev
one
publish
report
provid
data
need
laboratori
prepared
ie
sequenti
sampl
ct
valu
posit
neg
test
result
therefor
present
viral
shed
kinet
indirectli
deriv
fig
b
plot
timelin
avail
data
sampl
test
outcom
day
onset
symptom
merscov
patient
diagnos
uk
germani
franc
well
case
saudi
arabia
data
suggest
shed
kinet
may
similar
observ
sar
human
coronavirus
although
limit
inform
avail
latter
fig
review
also
suggest
use
upper
respiratori
specimen
merscov
eg
nasopharyng
swab
diagnosi
may
sensit
use
lower
respiratori
tract
specimen
fig
b
agreement
viral
load
higher
sampl
obtain
lower
respiratori
tract
compar
upper
respiratori
tract
merscov
case
difficulti
interpret
diagnost
test
result
illustr
two
secondari
case
franc
uk
respect
fig
patient
patient
sampl
earli
onset
symptom
np
specimen
posit
uk
case
neg
french
case
sputum
latter
posit
sar
although
sampl
test
npa
lower
respiratori
tract
specimen
often
pcr
posit
npa
upper
respiratori
tract
sampl
sar
diarrhoea
one
common
extrapulmonari
manifest
patient
progress
viral
load
peak
around
day
found
patient
stool
specimen
regardless
respiratori
symptom
fig
observ
children
hospit
hcov
suggest
gastrointestin
shed
limit
compar
sar
although
four
hcov
speci
detect
patient
stool
howev
compar
sar
less
inform
kinet
shed
viral
load
stool
respiratori
sampl
although
major
clinic
manifest
present
mer
patient
associ
respiratori
tract
gastrointestin
symptom
includ
diarrhoea
cours
ill
also
observ
quit
frequent
trigger
question
regard
use
stool
diagnos
merscov
avail
data
limit
compar
analysi
coronavirus
uae
patient
first
treat
abu
dhabi
hospit
march
later
hospit
germani
stool
sampl
test
borderlin
posit
day
onset
symptom
fig
patient
b
later
stool
sampl
patient
f
ksa
g
patient
transfer
qatar
uk
neg
rtpcr
whilst
diarrhoea
list
clinic
pictur
case
includ
two
separ
cluster
saudi
arabia
test
undertaken
mer
patient
specimen
urin
seraplasma
sampl
blood
rare
test
allow
consist
nucleotid
number
base
human
betacoronviru
strain
b
rdrpseqrnest
case
amplif
product
obtain
secondround
reaction
pcr
set
use
forward
primer
first
round
revers
primer
c
seqnfnest
case
amplif
product
obtain
secondround
reaction
pcr
set
use
forward
primer
revers
primer
first
round
conclus
tabl
urin
specimen
test
patient
transfer
germani
rtpcr
posit
day
day
renal
failur
seraplasma
sampl
collect
three
patient
late
diseas
progress
day
neg
patient
f
b
rtpcr
done
blood
one
french
patient
posit
day
establish
relev
cutoff
valu
test
also
take
consider
patient
group
differ
respect
age
comorbid
etc
earli
stage
outbreak
investig
observ
bias
sever
diseas
specif
group
patient
eg
older
patient
comorbid
sofar
major
report
mer
case
underli
diseas
andor
immunosuppress
could
explan
higher
case
fatal
rate
addit
delay
clearanc
viral
infect
risk
group
could
altern
explan
prolong
shed
observ
patient
describ
fig
patient
comorbid
often
nonsar
cov
infect
compar
otherwis
healthi
patient
may
shed
viru
prolong
period
time
sar
clinic
cours
among
patient
less
year
age
milder
less
aggress
compar
adult
teenag
kinet
viral
load
pattern
shed
differ
group
patient
influenc
interpret
diagnost
result
clinic
surveil
captur
sever
patient
outbreak
contain
requir
full
understand
divers
clinic
present
includ
mild
asymptomat
case
assess
shed
kinet
immunolog
respons
group
notori
difficult
requir
target
studi
willing
healthi
person
sampl
taken
without
proper
studi
unclear
instanc
asymptomat
person
contribut
transmiss
consider
differ
among
respiratori
virus
ratio
symptomat
asymptomat
infect
instanc
among
children
infect
caus
respiratori
syncyti
viru
rsv
human
metapneumoviru
usual
associ
clinic
ill
contrast
non
sar
cov
rhinoviru
human
bocaviru
commonli
found
asymptomat
children
well
literatur
kinet
antibodi
patient
sarscov
show
conflict
result
regard
time
appear
antibodi
accord
report
sarscov
antibodi
igg
igm
usual
detect
within
first
day
ill
increas
dramat
second
week
reach
peak
igg
level
within
day
fig
similarli
igm
antibodi
level
increas
month
declin
gradual
profil
observ
two
differ
serolog
assay
assur
detect
level
antibodi
affect
sensit
test
studi
found
specif
antibodi
igg
igm
iga
earli
day
onset
diseas
igg
neutralis
antibodi
may
persist
patient
month
although
titr
show
signific
declin
four
month
data
import
plan
serosurvey
may
take
sever
month
organis
due
protocol
design
ethic
clearanc
plan
studi
logist
presenc
antibodi
sarscov
individu
mild
symptom
describ
healthcar
worker
antibodi
level
measur
studi
highest
person
sever
ill
indic
differ
test
cutoff
may
need
use
laboratori
test
public
health
investig
aim
identifi
mild
case
well
base
epidemiolog
investig
includ
serolog
assess
extent
transmiss
conclus
symptomat
patient
effici
spreader
sar
viru
merscov
asymptomat
infect
recent
identifi
health
worker
children
n
whether
person
effici
transmit
infect
remain
unknown
antibodi
detect
assay
develop
use
limit
retrospect
studi
report
serolog
test
immunofluoresc
assay
serum
sampl
person
seek
medic
care
fakeeh
hospit
jeddah
saudi
arabia
first
case
mer
diagnos
two
previou
year
patient
test
neg
merscov
wherea
patient
confirm
merscov
infect
clear
antibodi
respons
igg
author
explain
lack
use
serolog
fact
assay
yet
valid
argument
seem
flaw
could
argu
pcr
assay
use
univers
limit
describ
serolog
test
confirm
infect
two
merscov
patient
abu
dhabi
qatar
hospit
germani
high
titr
antibodi
ifa
also
confirm
neutralis
test
microarray
test
interpret
merscov
serolog
hamper
widespread
circul
four
common
hcov
especi
belong
genu
betacoronavirus
crossreact
antibodi
shown
sarscov
coronaviru
depend
also
specif
assay
accord
guidanc
health
profession
patient
evalu
merscov
infect
develop
pneumonia
pneumon
fever
histori
travel
resid
arabian
peninsula
day
ill
onset
contact
known
confirm
probabl
mer
case
day
ill
onset
addit
recommend
test
novel
coronaviru
person
includ
health
care
worker
cluster
acut
respiratori
infect
unknown
aetiolog
requir
hospitalis
respiratori
infect
unexpectedli
sever
accord
mer
case
definit
revis
juli
confirm
case
requir
laboratori
confirm
molecular
method
includ
posit
realtim
reversetranscript
polymeras
chain
reaction
rrtpcr
least
two
specif
genom
target
tabl
singl
posit
target
sequenc
second
target
singl
posit
rrtpcr
without
confirm
consid
inconclus
merscov
laboratori
test
case
classifi
probabl
sever
molecular
assay
widespread
use
twostep
approach
screen
confirm
tabl
algorithm
recommend
cdc
algorithm
screen
pcr
target
region
upstream
e
gene
propos
sometim
combin
nucleocapsid
n
gene
base
pcr
enhanc
sensit
specimen
screen
confirm
second
assay
differ
set
primer
probe
recommend
tabl
serolog
assay
test
antibodi
mer
coronaviru
develop
differ
laboratori
expert
use
human
diagnost
well
tabl
howev
offici
recommend
current
avail
regard
serolog
test
valid
difficult
limit
avail
human
convalesc
sera
accord
case
definit
person
acut
febril
respiratori
ill
sever
posit
serolog
test
categoris
probabl
case
merscov
infect
whenev
possibl
pair
acut
convalesc
sera
test
ideal
combin
molecular
test
respiratori
sampl
specimen
test
describ
strongli
advis
lower
respiratori
specimen
collect
possibl
addit
nasopharyng
oropharyng
swab
specimen
collect
also
emphasis
repeat
test
initi
result
may
neg
specimen
send
refer
laboratori
confirm
probabl
confirm
case
mer
immedi
commun
nation
health
author
addit
request
confirm
probabl
case
report
within
h
classifi
region
contact
point
intern
health
regul
appropri
region
offic
advanc
laboratori
techniqu
past
decad
led
continu
improv
laboratori
prepared
emerg
infecti
diseas
howev
lack
suffici
detail
data
accompani
patient
notif
public
import
constraint
develop
evidencebas
diagnost
support
outbreak
investig
gain
better
understand
clinic
signific
epidemiolog
merscov
imper
collect
detail
data
sampl
laboratori
analys
result
combin
clinic
epidemiolog
data
order
improv
qualiti
laboratori
support
outbreak
full
valid
laboratori
assay
done
combin
use
molecular
serolog
approach
highli
recommend
acut
convalesc
serum
sampl
collect
patient
help
defin
kinet
seroconvers
help
confirm
rule
infect
futur
patient
avoid
misdiagnosi
fals
neg
test
result
due
low
sensit
earli
phase
infect
antibodi
level
low
control
nonspecif
reactiv
none
requir
